Zobrazeno 1 - 10
of 354
pro vyhledávání: '"Fumio, Imazeki"'
Autor:
Kazumasa, Sakamoto, Kiyoaki, Ito, Hiroshi, Yotsuyanagi, Hiroshi, Yatsuhashi, Yasuhito, Tanaka, Shuhei, Hige, Yasuhiro, Takikawa, Yoshiyuki, Ueno, Kazuhide, Yamamoto, Fumio, Imazeki, Jun, Inoue, Masayuki, Kurosaki, Takeji, Umemura, Hidenori, Toyoda, Eiji, Mita, Kojiro, Michitaka, Tatsuji, Maeshiro, Norie, Yamada, Atsushi, Suetsugu, Miwa, Kawanaka, Yuya, Seko, Kentaro, Matsuura, Akinori, Okumura, Yoshitaka, Fukuzawa, Masaya, Sugiyama, Masashi, Mizokami, Masashi, Yoneda
Publikováno v:
Journal of Gastroenterology. 57:971-980
Hepatitis B virus (HBV) is one of the most prevalent chronic viral infections that causes chronic hepatitis B (CHB). In Japan, genotypes B and C account for most of acute and chronic cases of hepatitis. However, previous studies showed that the preva
Autor:
Shingo Nakamoto, Fumio Imazeki, Makoto Arai, Shin Yasui, Masato Nakamura, Yuki Haga, Reina Sasaki, Tatsuo Kanda, Hiroshi Shirasawa, Osamu Yokosuka
Publikováno v:
International Journal of Molecular Sciences, Vol 16, Iss 9, Pp 21177-21190 (2015)
We examined whether hepatitis C virus (HCV) genotype 1b core- and NS5A-region mutations are associated with response to peginterferon α-2b plus ribavirin combination therapy. A total of 103 patients with high HCV genotype 1b viral loads (≥100 KIU/
Externí odkaz:
https://doaj.org/article/dbd421fca73d454d91f7aac73e9bb829
Autor:
Tatsuo Kanda, Masato Nakamura, Reina Sasaki, Shin Yasui, Shingo Nakamoto, Yuki Haga, Xia Jiang, Shuang Wu, Akinobu Tawada, Makoto Arai, Fumio Imazeki, Osamu Yokosuka
Publikováno v:
Case Reports in Gastroenterology, Vol 9, Iss 2, Pp 215-220 (2015)
Direct-acting antivirals with or without peginterferon α (PEG-IFN α) plus ribavirin are now available for the treatment of hepatitis C virus (HCV) infection. Direct-acting antivirals are potent inhibitors of HCV replication, but some of them occasi
Externí odkaz:
https://doaj.org/article/c00a0bc6bddc4d0c9713b57bf571e7e6
Autor:
Shingo Nakamoto, Tatsuo Kanda, Chiaki Nakaseko, Emiko Sakaida, Chikako Ohwada, Masahiro Takeuchi, Yusuke Takeda, Naoya Mimura, Tohru Iseki, Shuang Wu, Makoto Arai, Fumio Imazeki, Kengo Saito, Hiroshi Shirasawa, Osamu Yokosuka
Publikováno v:
International Journal of Molecular Sciences, Vol 15, Iss 11, Pp 21455-21467 (2014)
We retrospectively reviewed 413 recipients with hematologic malignancies who underwent hematopoietic stem cell transplantation (HSCT) between June 1986 and March 2013. Recipients with antibody to hepatitis B core antigen (anti-HBc) and/or to hepatiti
Externí odkaz:
https://doaj.org/article/1028f3ab795a466abdd4236d0376f023
Autor:
Tatsuo Kanda, Shingo Nakamoto, Shin Yasui, Masato Nakamura, Tatsuo Miyamura, Shuang Wu, Xia Jiang, Makoto Arai, Fumio Imazeki, Osamu Yokosuka
Publikováno v:
Case Reports in Oncology, Vol 7, Iss 2, Pp 288-296 (2014)
The use of phlebotomy is relatively common for ‘difficult-to-treat by antiviral therapies' hepatitis C virus (HCV)-infected patients and for certain patients having chronic liver diseases with an iron overload of the liver. In the present study, we
Externí odkaz:
https://doaj.org/article/98fe58a014b54c80a49960c8d7a0cf3a
Autor:
Masahiro Hayashi, Tatsuo Kanda, Masato Nakamura, Tatsuo Miyamura, Shin Yasui, Shingo Nakamoto, Shuang Wu, Makoto Arai, Fumio Imazeki, Osamu Yokosuka
Publikováno v:
Case Reports in Gastroenterology, Vol 8, Iss 1, Pp 129-133 (2014)
Some patients with alcohol dependence may initially present with atypical laboratory and histological features resembling autoimmune hepatitis (AIH) or drug-induced liver injury (DILI). Even with liver biopsy, it may be difficult to diagnose certain
Externí odkaz:
https://doaj.org/article/e511d258c69c4b05b441da4700bc8bb6
Autor:
Taichi Fukushima, Hideyuki Hashimoto, Gaku Tanaka, Takeshi Nagashima, Masayuki Otsuka, Mamoru Takada, Yasuyuki Hirai, Fumio Imazeki
Publikováno v:
Breast Cancer (Tokyo, Japan)
BackgroundThe novel coronavirus disease 2019 (COVID-19) undermines the benefits of cancer screening. To date, no study has identified specific infection control methods. We aimed to provide practical methods for COVID-19 risk reduction during breast
Publikováno v:
International Journal of Medical Sciences, Vol 10, Iss 1, Pp 43-49 (2013)
Some patients infected with hepatitis C virus (HCV) genotype 2 could be cured with treatment shorter than 24 weeks using peginterferon plus ribavirin, but there are still treatment-refractory patients. Direct-acting antivirals (DAAs) are not currentl
Externí odkaz:
https://doaj.org/article/501b51c9587f4e0bb4c0cd099abd517d
Autor:
Osamu Yokosuka, Fumio Imazeki, Makoto Arai, Keiichi Fujiwara, Xia Jiang, Shuang Wu, Shingo Nakamoto, Tatsuo Kanda, Tatsuo Miyamura
Publikováno v:
Viruses, Vol 4, Iss 8, Pp 1264-1278 (2012)
It has been reported that inosine triphosphatase (ITPA) gene variants protect against ribavirin-induced anemia in patients treated for chronic hepatitis C. IL28B variants also influence the treatment response of peginterferon plus ribavirin treatment
Externí odkaz:
https://doaj.org/article/d0e0c0ee0f0b405f94eac7de349558fc
Autor:
Toru Wakamatsu, Tatsuo Kanda, Akinobu Tawada, Tatsuo Miyamura, Masanori Takahashi, Tetsuhiro Chiba, Makoto Arai, Hitoshi Maruyama, Keiichi Fujiwara, Fumio Imazeki, Osamu Yokosuka
Publikováno v:
Case Reports in Gastroenterology, Vol 6, Iss 2, Pp 394-399 (2012)
Antimitochondrial antibody (AMA) is one of the representative features of primary biliary cirrhosis (PBC). PBC is a female-dominant disease usually presenting intrahepatic bile duct destruction, cholestasis and fibrosis with or without chronic nonsup
Externí odkaz:
https://doaj.org/article/4323eb66abaa4acc8a73ce5742a4cabb